CARLSBAD, Calif., Jan. 13, 2017 -- Aurora Spine Corporation (TSXV:ASG) announced today the allowance of its United States Patent Application No.: 14/732,240 entitled “POLYAXIAL INTERSPINOUS FUSION IMPLANT AND BONE GROWTH STIMULATION SYSTEM.” In addition to Aurora’s implant family of ZIP® ISPs, including its ZIP Ultra®, ZIP 51™, ZIP LP™ and Dyna-ZIP™, this patent application covers the company’s first polyaxial implant design.
“The polyaxial ZIP® Interspinous patent allowance is another milestone in Aurora Spine’s history. Our latest patent will be issued for our newest interspinous device design that permits for full polyaxial maneuverability of the implant components in difficult situations during minimally invasive fusion cases. The newly allowed patent features our already patented ONE-STEP™ locking mechanism that eliminates the use of a set screw in Aurora’s Screwless Procedure™ surgeries,” said Laszlo Garamszegi, Chief Technology Officer of Aurora Spine.
“Aurora is changing spine surgery, and we are thrilled that our newest patent has been allowed by the United States Patent and Trademark Office (USPTO). This patent further validates the modern advancements of our Screwless technology,” said Trent Northcutt, President and CEO of Aurora Spine, “and it maintains our commitment to introduce advanced, minimally invasive spine surgery technologies.”
This is Aurora’s second allowed U.S. patent. Aurora Spine has several other U.S. and international patent applications pending directed to the ZIP system and its future technologies.
About Aurora Spine
Aurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of screwless, innovative, minimally invasive, regenerative spinal implant technologies. Aurora Spine continues to position itself at the forefront of spinal surgery procedures, focusing on minimally invasive spine surgery technologies. Aurora Spine is changing spine surgery by focusing on disruptive technologies following the Company’s commitment to – Simplifying the Complex.
Forward-Looking Statements
This news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Information" in Aurora Spine's final prospectus (collectively, "forward-looking information"). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine's securities about important factors that could cause Aurora Spine's actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.
For more information, please contact: Aurora Spine Corporation Trent Northcutt President and Chief Executive Officer (760) 424-2004 Eric Fronk Chief Financial Officer (760) 424-2004 www.aurora-spine.com


Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
First Western Ship Transits Strait of Hormuz Since Iran War Began
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Apple Turns 50: From Garage Startup to AI Crossroads
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 



